Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a brand-name tablet prescribed for HIV-1. As with other drugs, Biktarvy can cause side effects, such as ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a prescription drug that’s used to treat HIV. This drug can interact with other medications and some ...

For treating HIV, the recommended Biktarvy dosage is one tablet taken once per day. Taking Biktarvy at about the same time each day is recommended. Biktarvy is a complete treatment for HIV ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

Data showed a treatment ... a first-in-class HIV-1 capsid inhibitor. This open-label, active-controlled study enrolled virologically suppressed adults who were on Biktarvy (bictegravir 50 mg ...

The proportion of individuals with HIV-1 RNA less than ... who switched to treatment with once-weekly islatravir and lenacapavir (ISL + LEN) or continued Biktarvy maintained comparable high ...

Gilead Sciences Inc (GILD) reports robust financial performance with significant sales growth in key therapeutic areas and ...

Meanwhile, Gilead's HIV treatment, Biktarvy, retains a very large share ... overall survival compared with chemotherapy, Gilead Chief Commercial Officer Johanna Mercier reported last month.